1887

Abstract

The aim of this paper was to determine the correlation between serum cryptococcal antigen and a diagnosis of cryptococcal meningitis in the immunocompetent cohort. A retrospective multicentre analysis of immunocompetent patients diagnosed and treated for cryptococcal meningitis between January 2000 and December 2017 was performed. Sixty-seven of the 143 cases of cryptococcosis occurred in immunocompetent patients. The serum cryptococcal antigen titre was significantly higher in the meningitis group [1 : 256 (IQR: 64–1024)] compared with that for non-meningitis patients [1 : 64 (IQR: 8–256)], P=0.012. The relative risk of meningitis with a serum cryptococcal antigen (CRAG) >1 : 64 was 1.8 (95 % CI: 1.15–2.82). This study demonstrates a clear correlation between serum cryptococcal antigen titre and meningitis. While the serum titre is not definitive for meningitis, in resource-limited settings or cases where lumbar puncture may be contraindicated, this evidence may aid diagnosis and subsequent therapeutic decisions.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000830
2018-08-23
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/10/1515.html?itemId=/content/journal/jmm/10.1099/jmm.0.000830&mimeType=html&fmt=ahah

References

  1. Nguyen MH, Husain S, Clancy CJ, Peacock JE, Hung CC et al. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect 2010;61:419–426 [CrossRef][PubMed]
    [Google Scholar]
  2. Heitman J. Cryptococcus: From Human Pathogen to Model Yeast Washington: ASM Press; 2011
    [Google Scholar]
  3. Gassiep I, McDougall D, Douglas J, Francis R, Playford EG. Cryptococcal infections in solid organ transplant recipients over a 15-year period at a state transplant center. Transpl Infect Dis 2017;19:e12639 [CrossRef]
    [Google Scholar]
  4. Bratton EW, El Husseini N, Chastain CA, Lee MS, Poole C et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One 2012;7:e43582 [CrossRef][PubMed]
    [Google Scholar]
  5. Chen SC.Australasian Society for Infectious Diseases (ASID) Mycoses Iterest Group Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal Amphotericin B. J Antimicrob Chemother 2002;49:57–61 [CrossRef][PubMed]
    [Google Scholar]
  6. Chen SC, Slavin MA, Heath CH, Playford EG, Byth K et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012;55:789–798 [CrossRef][PubMed]
    [Google Scholar]
  7. Aye C, Henderson A, Yu H, Norton R. Cryptococcosis-the impact of delay to diagnosis. Clin Microbiol Infect 2016;22:632–635 [CrossRef][PubMed]
    [Google Scholar]
  8. Gassiep I, Douglas J, Emeto TI, Crawley K, Playford EG. Cryptococcal infections over a 15 year period at a tertiary facility & impact of guideline management. Mycoses 2018;61:633–638 [CrossRef]
    [Google Scholar]
  9. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009;48:856–862 [CrossRef][PubMed]
    [Google Scholar]
  10. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–1821 [CrossRef][PubMed]
    [Google Scholar]
  11. Klein KR, Hall L, Deml SM, Rysavy JM, Wohlfiel SL et al. Identification of Cryptococcus gattii by use of L-canavanine glycine bromothymol blue medium and DNA sequencing. J Clin Microbiol 2009;47:3669–3672 [CrossRef][PubMed]
    [Google Scholar]
  12. Westblade LF, Jennemann R, Branda JA, Bythrow M, Ferraro MJ et al. Multicenter study evaluating the Vitek MS system for identification of medically important yeasts. J Clin Microbiol 2013;51:2267–2272 [CrossRef][PubMed]
    [Google Scholar]
  13. Baddley JW, Perfect JR, Oster RA, Larsen RA, Pankey GA et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008;27:937–943 [CrossRef][PubMed]
    [Google Scholar]
  14. Lu CH, Chang WN, Chang HW, Chuang YC. The prognostic factors of cryptococcal meningitis in HIV-negative patients. J Hosp Infect 1999;42:313–320 [CrossRef][PubMed]
    [Google Scholar]
  15. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010;50:291–322 [CrossRef][PubMed]
    [Google Scholar]
  16. Jitmuang A, Panackal AA, Williamson PR, Bennett JE, Dekker JP et al. Performance of the Cryptococcal Antigen Lateral Flow Assay in Non-HIV-Related Cryptococcosis. J Clin Microbiol 2016;54:460–463 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000830
Loading
/content/journal/jmm/10.1099/jmm.0.000830
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error